Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 75 of 113 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/17
End: 08/31/18
Due: 08/31/19
Phase: N/A
Priority: Normal
Start: 10/01/20
End: 09/01/21
Due: 09/01/22
Phase: N/A
Priority: Normal
Start: 04/30/13
End: 12/31/13
Due: 12/31/14
Phase: N/A
Priority: Normal
Start: 04/17/18
End: 02/28/20
Due: 02/28/21
Phase: N/A
Priority: Normal
Start: 02/01/25
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 05/27/23
End: 08/31/25
Due: 08/31/26
Phase: N/A
Priority: Normal
Start: 06/01/22
End: 02/01/23
Due: 02/01/24
Phase: N/A
Priority: Normal
Start: 08/24/23
End: 08/31/24
Due: 08/31/25
Phase: N/A
Priority: Normal
Start: 07/01/17
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 01/02/16
End: 06/23/16
Due: 06/23/17
Phase: N/A
Priority: Normal
Start: 10/30/23
End: 12/30/24
Due: 12/30/25
Phase: N/A
Priority: Normal
Start: 07/12/20
End: 01/30/21
Due: 01/30/22
Phase: N/A
Priority: Normal
Start: 01/01/20
End: 07/01/22
Due: 07/01/23
Phase: N/A
Priority: Normal
Start: 03/13/20
End: 01/10/22
Due: 01/10/23
Phase: N/A
Priority: Normal
Start: 10/20/19
End: 02/20/21
Due: 02/20/22
Phase: N/A
Priority: Normal
Start: 05/01/21
End: 07/10/22
Due: 07/10/23
Phase: N/A
Priority: Normal
Start: 10/10/19
End: 09/15/20
Due: 09/15/21
Phase: N/A
Priority: Normal
Start: 01/01/19
End: 07/31/19
Due: 07/31/20
Phase: N/A
Priority: Normal
Start: 01/01/19
End: 07/31/19
Due: 07/31/20
Phase: N/A
Priority: Normal
Start: 10/01/23
End: 12/27/23
Due: 12/27/24
Phase: N/A
Priority: Normal
Start: 10/31/16
End: 07/31/18
Due: 07/31/19
Phase: N/A
Priority: Normal
Start: 09/21/23
End: 07/30/24
Due: 07/30/25
Phase: N/A
Priority: Normal
Start: 03/01/18
End: 12/31/18
Due: 12/31/19
Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study
Phase: N/A
Priority: Normal
Start: 01/01/22
End: 03/01/24
Due: 03/01/25
Phase: N/A
Priority: Normal
Start: 10/01/22
End: 09/30/23
Due: 09/30/24